Epigenetic disease markers in primary sclerosing cholangitis and primary biliary cholangitis-methylomics of cholestatic liver disease.

Autor:	Juran BD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., McCauley BM; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA., Atkinson EJ; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA., Schlicht EM; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Bianchi JK; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Vollenweider JM; Genome Analysis Core, Mayo Clinic, Rochester, Minnesota, USA., Ye H; Genome Analysis Core, Mayo Clinic, Rochester, Minnesota, USA., LaRusso NF; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Gores GJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Sun Z; Division of Computational Biology, Mayo Clinic, Rochester, Minnesota, USA., Lazaridis KN; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Jazyk:	angličtina
Zdroj:	Hepatology communications [Hepatol Commun] 2024 Jul 18; Vol. 8 (8). Date of Electronic Publication: 2024 Jul 18 (Print Publication: 2024).
DOI:	10.1097/HC9.0000000000000496
Abstrakt:	Background: The epigenome, the set of modifications to DNA and associated molecules that control gene expression, cellular identity, and function, plays a major role in mediating cellular responses to outside factors. Thus, evaluation of the epigenetic state can provide insights into cellular adaptions occurring over the course of disease. Methods: We performed epigenome-wide association studies of primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) using the Illumina MethylationEPIC Bead Chip. Results: We found evidence of increased epigenetic age acceleration and differences in predicted immune cell composition in patients with PSC and PBC. Epigenetic profiles demonstrated differences in predicted protein levels including increased levels of tumor necrosis factor receptor superfamily member 1B in patients with cirrhotic compared to noncirrhotic PSC and PBC. Epigenome-wide association studies of PSC discovered strongly associated 5'-C-phosphate-G-3' sites in genes including vacuole membrane protein 1 and SOCS3, and epigenome-wide association studies of PBC found strong 5'-C-phosphate-G-3' associations in genes including NOD-like receptor family CARD domain containing 5, human leukocyte antigen-E, and PSMB8. Analyses identified disease-associated canonical pathways and upstream regulators involved with immune signaling and activation of macrophages and T-cells. A comparison of PSC and PBC data found relatively little overlap at the 5'-C-phosphate-G-3' and gene levels with slightly more overlap at the level of pathways and upstream regulators. Conclusions: This study provides insights into methylation profiles of patients that support current concepts of disease mechanisms and provide novel data to inspire future research. Studies to corroborate our findings and expand into other -omics layers will be invaluable to further our understanding of these rare diseases with the goal to improve and individualize prognosis and treatment. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu